Uranium Spot Price Climbing

Source: Uranium Investing News, Dave Brown (11/17/10)

"The spot uranium price continued its ascent for a successive week."

The spot uranium price continued its ascent for a successive week, with a slower growth rate as the value increased by $1.75 to $59.25/lb. Six transactions were concluded this week, with financial entities and traders purchasing the bulk of the material sold. With some uncertainty on supply and demand fundamentals, the delivery timing continues to be a significant factor in the spot market. Shorter-term uranium supplies for delivery by year-end 2010 are extremely thinly traded—and the emergence of significant mid- and long-term demand, combined with buyers competing to purchase material, continues to command upward pressure on prices.

Chinese appetite for secure energy sources continues to generate headlines with investors and the nuclear industry, following an announcement last Thursday that China Guangdong Nuclear Power Group signed a contract with Kazakhstan's Kazatomprom. Exact details of the exchange were unavailable; however, the long-term contract was signed after a meeting between the Chinese chief political adviser Jia Qinglin and Kazakh Prime Minister Karim Massimov.

Australia can now commence supplying uranium to fuel Russia's power reactors following the exchange of ratification notes by the Australian Prime Minister Julia Gillard and Russian President Dmitry Medvedev formalizing a bilateral nuclear cooperation agreement.

The meeting in Seoul, South Korea occurred prior to the start of the recent G20 summit. During the exchange, Medvedev said: "To open a new page in relations, today is a good opportunity to exchange instruments of ratification of the agreement, which was previously agreed and accepted." Gillard was pleased, saying: "It will increase export opportunities and create jobs for Australia's uranium suppliers and consolidates Australia's position as a reliable provider of energy resources." She also noted that the agreement brought Australia's bilateral nuclear relationship with Russia into line with agreements in place with other countries, including the U.S., China, Japan and South Korea.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.